JP2011522888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522888A5 JP2011522888A5 JP2011513493A JP2011513493A JP2011522888A5 JP 2011522888 A5 JP2011522888 A5 JP 2011522888A5 JP 2011513493 A JP2011513493 A JP 2011513493A JP 2011513493 A JP2011513493 A JP 2011513493A JP 2011522888 A5 JP2011522888 A5 JP 2011522888A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- groups
- methyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 125000002950 monocyclic group Chemical group 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- -1 c b Chemical group 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- VRCZLPVQUNNREW-UHFFFAOYSA-N 12-[4-(4-methylpiperazin-1-yl)phenyl]-3,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene-4-carbonitrile Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=NC(=CC=C4NC3=NC=2)C#N)C=C1 VRCZLPVQUNNREW-UHFFFAOYSA-N 0.000 claims 1
- SUZJJFSEMWCPNP-UHFFFAOYSA-N 12-[4-(4-methylpiperazin-1-yl)phenyl]-4-(1-methylpyrazol-3-yl)-3,5,8,10-tetrazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,10,12-pentaen-6-one Chemical compound CN1CCN(CC1)c1ccc(cc1)-c1cnc2[nH]c3c(nc([nH]c3=O)-c3ccn(C)n3)c2c1 SUZJJFSEMWCPNP-UHFFFAOYSA-N 0.000 claims 1
- KAHXPBJJOGXZLK-UHFFFAOYSA-N 12-[4-(4-methylpiperazin-1-yl)phenyl]-4-(2-methylpyrazol-3-yl)-3,5,8,10-tetrazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,10,12-pentaen-6-one Chemical compound CN1CCN(CC1)c1ccc(cc1)-c1cnc2[nH]c3c(nc([nH]c3=O)-c3ccnn3C)c2c1 KAHXPBJJOGXZLK-UHFFFAOYSA-N 0.000 claims 1
- TXNDZVYZZLWBTK-UHFFFAOYSA-N 12-bromo-4-(1-methylpyrazol-3-yl)-3,5,8,10-tetrazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,10,12-pentaen-6-one Chemical compound Cn1ccc(n1)-c1nc2c3cc(Br)cnc3[nH]c2c(=O)[nH]1 TXNDZVYZZLWBTK-UHFFFAOYSA-N 0.000 claims 1
- YCWZHHSOULJUNZ-UHFFFAOYSA-N 12-bromo-4-(2-methylpyrazol-3-yl)-3,5,8,10-tetrazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,10,12-pentaen-6-one Chemical compound Cn1nccc1-c1nc2c3cc(Br)cnc3[nH]c2c(=O)[nH]1 YCWZHHSOULJUNZ-UHFFFAOYSA-N 0.000 claims 1
- SVWXFUREAWPDOW-UHFFFAOYSA-N 2-(1-methylpyrazol-4-yl)-8-[4-(piperidin-1-ylmethyl)phenyl]-1,5-dihydropyrido[2,3]pyrrolo[2,4-b]pyrimidin-4-one Chemical compound C1=NN(C)C=C1C(N1)=NC(=O)C2=C1C1=CC(C=3C=CC(CN4CCCCC4)=CC=3)=CN=C1N2 SVWXFUREAWPDOW-UHFFFAOYSA-N 0.000 claims 1
- IYCXGQZWOGYFSH-UHFFFAOYSA-N 2-(1-methylpyrazol-4-yl)-8-[4-(piperidin-1-ylmethyl)phenyl]-5h-pyrido[4,5]pyrrolo[1,2-d]pyrimidine Chemical compound C1=NN(C)C=C1C1=NC=C(NC=2C3=CC(=CN=2)C=2C=CC(CN4CCCCC4)=CC=2)C3=N1 IYCXGQZWOGYFSH-UHFFFAOYSA-N 0.000 claims 1
- QZLMKMURPTUNHK-UHFFFAOYSA-N 2-[1-[(4-methoxyphenyl)methyl]pyrazol-4-yl]-8-[4-(4-methylpiperazin-1-yl)phenyl]-1,5-dihydropyrido[2,3]pyrrolo[2,4-b]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1CN1N=CC(C=2NC=3C4=CC(=CN=C4NC=3C(=O)N=2)C=2C=CC(=CC=2)N2CCN(C)CC2)=C1 QZLMKMURPTUNHK-UHFFFAOYSA-N 0.000 claims 1
- OTWLWCNHDNQNFV-UHFFFAOYSA-N 4-chloro-2-(1-methylpyrazol-4-yl)-8-[4-(piperidin-1-ylmethyl)phenyl]-5h-pyrido[2,3]pyrrolo[2,4-b]pyrimidine Chemical compound C1=NN(C)C=C1C1=NC(Cl)=C(NC=2C3=CC(=CN=2)C=2C=CC(CN4CCCCC4)=CC=2)C3=N1 OTWLWCNHDNQNFV-UHFFFAOYSA-N 0.000 claims 1
- JZXCUAXRQTZRMK-UHFFFAOYSA-N 4-chloro-8-[4-(4-methylpiperazin-1-yl)phenyl]-2-(1-methylpyrazol-4-yl)-5h-pyrido[2,3]pyrrolo[2,4-b]pyrimidine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=NC(=NC(Cl)=C4NC3=NC=2)C2=CN(C)N=C2)C=C1 JZXCUAXRQTZRMK-UHFFFAOYSA-N 0.000 claims 1
- TWZOGBRUQMLDLI-UHFFFAOYSA-N 4-chloro-8-[4-(4-methylpiperazin-1-yl)phenyl]-2-(1h-pyrazol-4-yl)-5h-pyrido[2,3]pyrrolo[2,4-b]pyrimidine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=NC(=NC(Cl)=C4NC3=NC=2)C2=CNN=C2)C=C1 TWZOGBRUQMLDLI-UHFFFAOYSA-N 0.000 claims 1
- DDGVPZWMJCOHFQ-UHFFFAOYSA-N 4-chloro-8-[4-(4-methylpiperazin-1-yl)phenyl]-2-(2-methylpyrazol-3-yl)-5h-pyrido[2,3]pyrrolo[2,4-b]pyrimidine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=NC(=NC(Cl)=C4NC3=NC=2)C=2N(N=CC=2)C)C=C1 DDGVPZWMJCOHFQ-UHFFFAOYSA-N 0.000 claims 1
- PVFMWZKSCAHMFL-UHFFFAOYSA-N 4-chloro-8-[4-(4-methylpiperazin-1-yl)phenyl]-2-pyridin-3-yl-5h-pyrido[2,3]pyrrolo[2,4-b]pyrimidine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=NC(=NC(Cl)=C4NC3=NC=2)C=2C=NC=CC=2)C=C1 PVFMWZKSCAHMFL-UHFFFAOYSA-N 0.000 claims 1
- HXIPOURWZRATPT-UHFFFAOYSA-N 4-methyl-8-[4-(4-methylpiperazin-1-yl)phenyl]-2-(1-methylpyrazol-4-yl)-5h-pyrido[4,5]pyrrolo[1,2-d]pyrimidine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=NC(=NC(C)=C4NC3=NC=2)C2=CN(C)N=C2)C=C1 HXIPOURWZRATPT-UHFFFAOYSA-N 0.000 claims 1
- FYYFJNPFTKUUOG-UHFFFAOYSA-N 8-[4-(4-methylpiperazin-1-yl)phenyl]-2-(1-methylpyrazol-3-yl)-5h-pyrido[4,5]pyrrolo[1,2-d]pyrimidine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=NC(=NC=C4NC3=NC=2)C2=NN(C)C=C2)C=C1 FYYFJNPFTKUUOG-UHFFFAOYSA-N 0.000 claims 1
- UHPKDZSLPXKOFD-UHFFFAOYSA-N 8-[4-(4-methylpiperazin-1-yl)phenyl]-2-(1-methylpyrazol-4-yl)-1,5-dihydropyrido[2,3]pyrrolo[2,4-b]pyrimidin-4-one Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=C(C(N=C(N4)C4=CN(C)N=C4)=O)NC3=NC=2)C=C1 UHPKDZSLPXKOFD-UHFFFAOYSA-N 0.000 claims 1
- RCJHIFFYXCUBMI-UHFFFAOYSA-N 8-[4-(4-methylpiperazin-1-yl)phenyl]-2-(1h-pyrazol-4-yl)-5h-pyrido[4,5]pyrrolo[1,2-d]pyrimidine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=NC(=NC=C4NC3=NC=2)C2=CNN=C2)C=C1 RCJHIFFYXCUBMI-UHFFFAOYSA-N 0.000 claims 1
- HMVHRSIRUWIFMC-UHFFFAOYSA-N 8-[4-(4-methylpiperazin-1-yl)phenyl]-2-(2-methylpyrazol-3-yl)-5h-pyrido[4,5]pyrrolo[1,2-d]pyrimidine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=NC(=NC=C4NC3=NC=2)C=2N(N=CC=2)C)C=C1 HMVHRSIRUWIFMC-UHFFFAOYSA-N 0.000 claims 1
- QIAOHWLWXSYDSV-UHFFFAOYSA-N 8-[4-(4-methylpiperazin-1-yl)phenyl]-2-pyridin-3-yl-1,5-dihydropyrido[2,3]pyrrolo[2,4-b]pyrimidin-4-one Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C3C4=C(C(N=C(N4)C=4C=NC=CC=4)=O)NC3=NC=2)C=C1 QIAOHWLWXSYDSV-UHFFFAOYSA-N 0.000 claims 1
- UAIMRIUSFMTVER-UHFFFAOYSA-N 8-bromo-2-(1-methylpyrazol-4-yl)-1,5-dihydropyrido[2,3]pyrrolo[2,4-b]pyrimidin-4-one Chemical compound C1=NN(C)C=C1C(N1)=NC(=O)C2=C1C1=CC(Br)=CN=C1N2 UAIMRIUSFMTVER-UHFFFAOYSA-N 0.000 claims 1
- HWGYMVNWFRGPOC-UHFFFAOYSA-N 8-bromo-2-[1-[(4-methoxyphenyl)methyl]pyrazol-4-yl]-1,5-dihydropyrido[2,3]pyrrolo[2,4-b]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1CN1N=CC(C=2NC=3C4=CC(Br)=CN=C4NC=3C(=O)N=2)=C1 HWGYMVNWFRGPOC-UHFFFAOYSA-N 0.000 claims 1
- YOPLIAQFMNTBFT-UHFFFAOYSA-N 8-bromo-2-pyridin-3-yl-1,5-dihydropyrido[2,3]pyrrolo[2,4-b]pyrimidin-4-one Chemical compound C12=CC(Br)=CN=C2NC(C(N=2)=O)=C1NC=2C1=CC=CN=C1 YOPLIAQFMNTBFT-UHFFFAOYSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- IFGGMDIZTDIOSI-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C=1C=NC=2NC3=CN=C(N=C3C2C1)C=1C=NN(C1)C.CN1CCN(CC1)C1=CC=C(C=C1)C=1C=NC=2NC3=CN=C(N=C3C2C1)C=1C=NC=CC1 Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C=1C=NC=2NC3=CN=C(N=C3C2C1)C=1C=NN(C1)C.CN1CCN(CC1)C1=CC=C(C=C1)C=1C=NC=2NC3=CN=C(N=C3C2C1)C=1C=NC=CC1 IFGGMDIZTDIOSI-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 239000012623 DNA damaging agent Substances 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6075008P | 2008-06-11 | 2008-06-11 | |
| US61/060,750 | 2008-06-11 | ||
| US14800409P | 2009-01-28 | 2009-01-28 | |
| US61/148,004 | 2009-01-28 | ||
| PCT/US2009/003481 WO2009151589A1 (en) | 2008-06-11 | 2009-06-10 | Diazacarbazoles and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014103195A Division JP2014196309A (ja) | 2008-06-11 | 2014-05-19 | ジアザカルバゾール及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011522888A JP2011522888A (ja) | 2011-08-04 |
| JP2011522888A5 true JP2011522888A5 (enExample) | 2012-07-26 |
| JP5677945B2 JP5677945B2 (ja) | 2015-02-25 |
Family
ID=41066268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513493A Expired - Fee Related JP5677945B2 (ja) | 2008-06-11 | 2009-06-10 | ジアザカルバゾール及びその使用方法 |
| JP2014103195A Pending JP2014196309A (ja) | 2008-06-11 | 2014-05-19 | ジアザカルバゾール及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014103195A Pending JP2014196309A (ja) | 2008-06-11 | 2014-05-19 | ジアザカルバゾール及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110124654A1 (enExample) |
| EP (1) | EP2324024B1 (enExample) |
| JP (2) | JP5677945B2 (enExample) |
| KR (2) | KR20110015699A (enExample) |
| CN (1) | CN102119162B (enExample) |
| AU (1) | AU2009258115B2 (enExample) |
| BR (1) | BRPI0909957A2 (enExample) |
| CA (1) | CA2726114A1 (enExample) |
| ES (1) | ES2392489T3 (enExample) |
| IL (1) | IL209548A (enExample) |
| MX (1) | MX2010013606A (enExample) |
| WO (1) | WO2009151589A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2324024B1 (en) * | 2008-06-11 | 2012-09-26 | Genentech, Inc. | Diazacarbazoles and methods of use |
| CA2817968C (en) | 2010-11-16 | 2019-03-12 | Array Biopharma Inc. | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
| GB201201566D0 (en) * | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| JP6370772B2 (ja) * | 2012-04-23 | 2018-08-08 | ジェネンテック， インコーポレイテッド | 化合物の調製のための中間体及び方法 |
| CN105189474A (zh) * | 2013-01-23 | 2015-12-23 | 芝加哥大学 | 用于抑制人铜转运蛋白atox1和ccs的方法和组合物 |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| PT3055308T (pt) | 2013-10-08 | 2018-01-18 | Hoffmann La Roche | Resumo |
| JP6840931B2 (ja) * | 2015-03-09 | 2021-03-10 | 東ソー株式会社 | 縮環芳香族化合物の製造方法 |
| US20170067946A1 (en) * | 2015-06-08 | 2017-03-09 | Zac WHEELER | Monitoring system with low power usage |
| EA201990187A1 (ru) | 2016-07-01 | 2019-07-31 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| ES2847903T3 (es) | 2016-09-09 | 2021-08-04 | Hoffmann La Roche | Procedimiento para la preparación de 2-(6-nitropiridin-3-il)-9H-dipirido[2,3-b;3',4'-d]pirrol |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| EP4652997A3 (en) | 2020-05-19 | 2026-03-04 | Pharmacosmos Holding A/s | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| CN115572282B (zh) * | 2021-07-05 | 2024-07-09 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1268477B1 (en) | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| KR100826817B1 (ko) * | 2000-03-15 | 2008-05-02 | 사노피-아벤티스 도이칠란트 게엠베하 | 치환된 베타-카볼린 |
| CN100345830C (zh) * | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP2006517949A (ja) * | 2003-02-17 | 2006-08-03 | ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ | キナーゼ阻害剤としての四環系ピラゾール誘導体、前記誘導体の製造方法、および前記誘導体を含む医薬組成物 |
| AR049300A1 (es) * | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2009004329A1 (en) | 2007-07-02 | 2009-01-08 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
| EP2324024B1 (en) * | 2008-06-11 | 2012-09-26 | Genentech, Inc. | Diazacarbazoles and methods of use |
-
2009
- 2009-06-10 EP EP09762885A patent/EP2324024B1/en active Active
- 2009-06-10 JP JP2011513493A patent/JP5677945B2/ja not_active Expired - Fee Related
- 2009-06-10 ES ES09762885T patent/ES2392489T3/es active Active
- 2009-06-10 CA CA2726114A patent/CA2726114A1/en not_active Abandoned
- 2009-06-10 BR BRPI0909957A patent/BRPI0909957A2/pt not_active Application Discontinuation
- 2009-06-10 US US12/997,069 patent/US20110124654A1/en not_active Abandoned
- 2009-06-10 MX MX2010013606A patent/MX2010013606A/es active IP Right Grant
- 2009-06-10 WO PCT/US2009/003481 patent/WO2009151589A1/en not_active Ceased
- 2009-06-10 KR KR1020117000608A patent/KR20110015699A/ko not_active Withdrawn
- 2009-06-10 CN CN200980131217.3A patent/CN102119162B/zh not_active Expired - Fee Related
- 2009-06-10 AU AU2009258115A patent/AU2009258115B2/en not_active Ceased
- 2009-06-10 KR KR1020167015993A patent/KR101764556B1/ko not_active Expired - Fee Related
-
2010
- 2010-11-24 IL IL209548A patent/IL209548A/en not_active IP Right Cessation
-
2014
- 2014-05-19 JP JP2014103195A patent/JP2014196309A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522888A5 (enExample) | ||
| CA3215823A1 (en) | Heterocyclic derivative inhibitor and preparation method therefor and application thereof | |
| AU2018374456B2 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| AU2005278292B2 (en) | Novel substituted imidazole derivatives | |
| JP2014513704A5 (enExample) | ||
| JP2018507214A5 (enExample) | ||
| KR102516711B1 (ko) | P2x7 조절제 | |
| AU2020282473A1 (en) | Nitrogen-containing heterocyclic derivative regulator, preparation method therefor and application thereof | |
| TW202321242A (zh) | 雜環化合物及使用方法 | |
| AU2020276802A1 (en) | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | |
| JP2020527174A5 (enExample) | ||
| EP3818063A1 (en) | Fused pyrazine derivatives as a2a / a2b inhibitors | |
| FI3436461T3 (fi) | Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina | |
| JP2016514719A5 (enExample) | ||
| ES2271221T3 (es) | Derivados imidazo-pirimidina como ligandos para receptores gaba. | |
| JP2014530238A5 (enExample) | ||
| JP2022542396A (ja) | Ｃｄ３８の阻害剤としてのヘテロ二環式アミド | |
| JP2013515729A5 (enExample) | ||
| JP2008156336A5 (enExample) | ||
| JP2010513523A5 (enExample) | ||
| JP2011507854A5 (enExample) | ||
| RU2014119250A (ru) | Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака и иммунных и аутоиммунных заболеваний | |
| HRP20170349T1 (hr) | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| JP2012525367A5 (enExample) | ||
| JP2015511245A5 (enExample) |